ArticleSN comprehensive clinical medicine2020
Prevalence of Pulmonary Embolism in COVID-19: a Pooled Analysis.
Article in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- An Overview of Pediatric Pulmonary Complications During COVID-19 Pandemic: A Lesson for Future.Immunity, inflammation and disease · 2024Review
- Risk of arterial and venous thromboses after COVID-19.The Lancet. Infectious diseases · 2022Article
- Symptomatic Venous Thromboembolic Events in COVID-19 Patients after Hospital Discharge: Aspects to Consider.Reviews in cardiovascular medicine · 2022Review
- Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.Frontiers in medicine · 2022Review
- Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.Expert review of clinical pharmacology · 2021Article
- Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience.Healthcare (Basel, Switzerland) · 2021Article
- Pulmonary embolism in coronavirus disease 2019: the silent killer.Medical journal, Armed Forces India · 2021Article
- COVID-19-Associated Pulmonary Embolism in Pediatric Patients.Hospital pediatrics · 2021Observational
- Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.Critical care (London, England) · 2021Observational
- Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19.Viruses · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There remains a high risk of thrombosis in patients affected by the SARS-CoV-2 virus and recent reports have shown pulmonary embolism (PE) as a cause of sudden death in these patients. However, the pooled rate of this deadly and frequently underdiagnosed condition among COVID-19 patients remains largely unknown. Given the frequency with which pulmonary embolism has been reported as a fatal complication of severe coronavirus disease, we sought to ascertain the actual prevalence of this event in COVID-19 patients. Using PubMed/Medline, EMBASE, and SCOPUS, a thorough literature search was performed to identify the studies reporting rate of PE among COVID-19. Random effects models were obtained to perform a meta-analysis, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.